NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Atopic dermatitis, or eczema, is a chronic skin condition that is common in children but may occur at any age. It arises as a result of a complex interaction between genetic and environmental factors and poses a significant burden on patients’ quality of life. Itch is an enormous, unresolved symptom in atopic dermatitis, induced by inflammation and skin damage. Sweden's TIRmed Pharma AB has developed a non-steroid cream to resolve itch with topical application. The medication targets mild to moderate symptoms, has an excellent safety profile and is affordable and easy to self-apply. Moreover, as the solution interferes with the immune system in a selective manner, it dampens inflammation. The EU-funded TIR-C project proposes a feasibility study, the development of a commercialisation plan and the confirmation of the regulatory requirements needed for market approvals.